Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Irinotecan FOLFIRI in UGT1A1 Genotype-Selected mCRC
NCT01639326Phase 2Unknown
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jul 2012
- Primary completion
- Jul 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01639326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639326.